Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Launched by UNIVERSIDADE FEDERAL DO CEARA · Nov 19, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of both sexes, aged ≥ 18 years, who have undergone heart transplantation between January 2017 and December 2023 and are under the care of the Heart Transplant and Heart Failure Unit at Hospital de Messejana.
- Exclusion Criteria:
- • Patients who refuse to participate in the study, those with known hypersensitivity or intolerance to iSGLT2, individuals with type 1 diabetes mellitus, symptoms of hypotension, or systolic blood pressure below 80 mm Hg, an estimated glomerular filtration rate (eGFR) below 20 ml per minute per 1.73 m2 of body surface area, and pregnant women
About Universidade Federal Do Ceara
The Universidade Federal do Ceará (UFC) is a prestigious public research university located in Brazil, renowned for its commitment to advancing knowledge and innovation in various fields, including healthcare and clinical research. With a strong focus on interdisciplinary collaboration, UFC actively engages in clinical trials to evaluate new therapies and healthcare interventions, aiming to improve patient outcomes and contribute to the global medical community. The university's dedicated research teams leverage state-of-the-art facilities and ethical practices to ensure the integrity and success of their clinical studies, making significant strides in the fields of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fortaleza, Ceara, Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported